On Apr. 28, 2020, Entos Pharmaceuticals announced a collaboration with EpiVax. This partnership combined the Entos Fusogenix DNA delivery technology with optimized COVID-19 epitopes from EpiVax to generate a highly effective immune response against the novel coronavirus, while ensuring a high degree of safety.